Inhibikase Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Three and nine months ended September 30, 2023. The unaudited filing covers a clinical-stage pharmaceutical company developing risvodetinib (IkT-148009) for Parkinson’s disease and multiple system atrophy, and IkT-001Pro for stable-phase chronic myelogenous leukemia.
Financial Position and Key Metrics
| Metric | Q3 2023 | Nine months 2023 | Comparable period |
|---|---|---|---|
| Grant revenue | $79,569 | $260,500 | Q3 2022: $7,291; nine months 2022: $59,874 |
| Research and development expense | $3.23 million | $10.62 million | Q3 2022: $2.98 million; nine months 2022: $8.98 million |
| SG&A expense | $1.62 million | $5.33 million | Q3 2022: $1.54 million; nine months 2022: $4.87 million |
| Net loss | $4.60 million | $14.85 million | Q3 2022: $4.49 million; nine months 2022: $13.78 million |
| Net loss per share | $0.86 | $2.93 | Q3 2022: $1.06; nine months 2022: $3.26 |
| Net cash used in operating activities | Not separately reported | $14.64 million | Nine months 2022: $13.79 million |
- At September 30, 2023, cash and cash equivalents were $14.86 million and marketable securities were $1.97 million, compared with $7.19 million and $15.86 million, respectively, at December 31, 2022.
- Working capital was $14.81 million; accumulated deficit was $62.72 million.
- Total liabilities were $2.86 million, consisting primarily of accounts payable, accrued expenses and operating lease obligations. The filing reports no material debt financing; lease obligations totaled $270,043.
- Cash, cash equivalents and marketable securities totaled approximately $16.83 million at quarter-end. Management estimates existing working capital will fund normal operations into the fourth quarter of 2024, subject to assumptions and the timing of spending.
- The company has no product-sales revenue. Grant revenue represented 100% of reported revenue and was derived from U.S. government research grants.
- Operating and net margins are not meaningful for investor valuation because grant revenue is minimal relative to clinical development expenses and the company remains loss-making.
Material Changes Versus Prior Comparable Period
- Q3 grant revenue increased $72,278, or 991%, to $79,569; nine-month grant revenue increased $200,626, or 335%, to $260,500. The increase primarily reflected grant-funded preclinical MSA research.
- Q3 research and development expense increased 8% to $3.23 million, and nine-month expense increased 18% to $10.62 million, primarily because of the Phase 2a Parkinson’s disease 201 trial. Nine-month CML-related research expense increased substantially to $2.56 million from $705,492.
- Q3 SG&A increased 6% to $1.62 million; nine-month SG&A increased 9% to $5.33 million.
- Nine-month net loss increased 8% to $14.85 million, despite a $816,752 increase in interest income to $835,283 from U.S. Treasury securities and money market instruments.
- Cash increased by $7.67 million during the first nine months of 2023, supported by $8.54 million of net financing proceeds and $13.77 million of net investing cash inflows, partially offset by $14.64 million of operating cash use.
- The company raised approximately $8.6 million in net proceeds from its January 2023 offering of common stock, pre-funded warrants and warrants. Shares outstanding increased to 5,360,326 at September 30, 2023 from 4,224,294 at December 31, 2022, before considering additional subsequent warrant exercises.
- A one-for-six reverse stock split became effective June 30, 2023. Historical share and per-share amounts were adjusted retroactively.
Guidance, Outlook, Risks and Unusual Items
- The Phase 2 Parkinson’s disease 201 trial had 28 open sites and approximately 20% enrollment as of the filing. Management reported 24 enrolled participants, five participants completing the 12-week dosing regimen, and plans to extend the study by 12 months, subject to additional financing.
- Management disclosed preliminary observations from 11 previously treated participants, including an average improvement relative to baseline for three participants receiving 200 mg. The company cautioned that the small sample size is insufficient to establish clinical benefit.
- Risvodetinib’s MSA program has an open IND, and the FDA granted Orphan Drug Designation in October 2023. The company is seeking funding and planning for a potential Phase 2 study.
- IkT-001Pro completed a 66-volunteer dose-finding and dose-equivalence study. Management stated that 600 mg and 900 mg doses produced bioequivalence to 400 mg and 600 mg of imatinib mesylate, respectively, and that it was preparing briefing materials for the FDA under the 505(b)(2) pathway.
- The company expects continued losses and rising research and development costs. Additional capital may be required through equity, debt, grants, licenses or collaborations. Failure to obtain funding could delay, reduce or discontinue clinical programs.
- The financial statements are prepared on a going-concern basis. Management’s cash runway estimate depends on clinical spending, future grants and financing assumptions that may not be achieved.
- Key risks include clinical-trial enrollment and outcomes, safety and efficacy, regulatory approval, manufacturing and third-party supplier dependence, intellectual-property protection, market acceptance, dilution from future financing, geopolitical disruption and financial-market volatility.
- The company reported no material litigation, no off-balance-sheet arrangements and no material changes in internal control over financial reporting. Disclosure controls were considered effective at a reasonable assurance level.
- The company issued 12,000 shares in September 2023 for digital media consulting services, valued at $17,280.
Important Facts for Investors to Verify
- Whether cash resources and the stated runway into the fourth quarter of 2024 remain adequate after changes in trial scope, enrollment and spending.
- The amount, timing and terms of any required capital raise, including potential dilution from common stock, pre-funded warrants and outstanding warrants.
- Actual enrollment, retention, safety data and efficacy results from the 201 Parkinson’s disease trial and any proposed 12-month extension.
- The regulatory status and FDA feedback for the IkT-001Pro 505(b)(2) pathway and the timing of any NDA submission.
- The funding, design and regulatory timeline for the planned MSA clinical program.
- The company’s continuing reliance on U.S. government grants for all reported revenue and its lack of commercial product revenue.
- The exercise, expiration and potential dilution associated with outstanding options and warrants; 3,916,003 shares were reserved for these instruments at September 30, 2023.